BMO Capital raised the firm’s price target on Neurocrine (NBIX) to $115 from $96 but keeps a Market Perform rating on the shares after its Q1 results. The company’s better-than-expected Crenessity revenues are likely to benefit shares near term, but Ingrezza 2025 commercial dynamics present challenges, the analyst tells investors in a research note, adding that to hit Ingrezza’s 2025 guide requires a change in the asset’s current growth trajectory.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $130 from $115 at Wedbush
- Neurocrine price target raised to $145 from $137 at RBC Capital
- Promising Growth Trajectory for Neurocrine: Buy Rating Justified by Strong Drug Performance and Innovative Trials
- Neurocrine price target raised to $152 from $137 at UBS
- Neurocrine price target raised to $165 from $155 at Guggenheim
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue